Injectable Bulking Agents Market

Injectable Bulking Agents Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment; 2018 - 2028

  • Ongoing
  • July 2020
  • REP-GB-6734
Injectable Bulking Agents Market

  • US$5,000
  • US$7,500
  • US$10,000

This Injectable Bulking Agents market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Injectable Bulking Agents market.

Injectable bulking agents are truly effective for female stress urinary incontinence, new injectable bulking agents show promise with regard to efficacy and durability

Injectable bulking agents are synthetic materials (bovine collagen, or autologous substances) that collaborate with the body's (mainly urinary) regular framework to treat and anticipate unusual stress and urinary incontinence in the body. Injectable bulking agents are injected periurethrally to increase the tissue bulk and thereby increase resistance to the outflow of urine. The bulking agent is injected into the per urethral tissue in the liquid form that then solidifies into a spongy material to bulk the urethral wall. Owing to the better and thorough understanding of the bio-chemical and physicochemical parameters by pharmaceutical scientists and better patient compliance, injectable bulking agents have gained considerable market share in the recent years. Injectable bulking agents are used as a preferred alternative over conventional surgical procedures and injectable drugs. Injectable bulking agents treat a useless urethra, this procedure is a negligibly obtrusive technique for revising natural sphincter disorder that outcomes in stretch urinary incontinence yet is being performed less every now and again in current practice. Injectable bulking agents are made of manufactured materials, ox-like collagen, or autologous substances, which expand the urethral divider and increment urethral protection from the urinary stream.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Growing Utilization of Up-to-date Injectable Bulking Agents

The major driver in injectable bulking agents market is the wide adoption of agents especially in the female patients with lower risk. Injectable bulking agents market has seen a steady growth and there is rapid expansion in product pipelines. Also, over the past decade, more patient-friendly, better biomaterial and synthetic form has enhanced demand for injectable bulking agents market. Its importance is recognized by both the academia and industry. Rising incidences of SUI (stress urinary incontinence) is also gaining traction. The lower efficacy and durability of bulking agents is balanced by low treatment morbidity with a favorable adverse event profile when compared to surgical management. Injectable bulking agents can help the gathering of patients that is unfit or unwilling to experience surgery for incontinence. The persistent advancement of systems and materials gives a ground to more up-to-date building operators. In like manner, late research has indicated guarantee in the utilization of undifferentiated organisms in periurethral infusions.

Prominent Viability, Wellbeing, and Cost Adequacy of Direct Acting Injectable Bulking Agents

The lower viability and strength of bulking agents is adjusted by low treatment morbidity when contrasted with surgical administration. Infusion is regularly performed through a transurethral approach with endoscopic perception. Injectable bulking agents are more suited to low-to-direct volume SUI and diligent SUI after earlier against incontinence methods. Geriatric patients with higher risk, or ineffectiveness to intrude on anticoagulation may profit by bulking if different interventions are not attainable. Different signs incorporate youth patients, who may want future pregnancy, or patients with a blend of SUI and deprived bladder emptying.

Regulatory Scenario with New Challenges

Various per urethral injectable bulking agents to treat urinary incontinence have been cleared by the FDA. Nonetheless, new products manufactured to date have not really met all the criteria of the perfect injectable bulking agents internationally. The main FDA-endorsed product was cross-linked collagen (e.g., Contigen). The bulking agent was observed to be retained after some time and indications could repeat, requiring extra infusions. The manufacturing of Contigen was officially suspended in 2011. Other per urethral injectable bulking agents cleared by FDA for urinary incontinence incorporate carbon-covered dots (e.g., Durasphere), circular particles of calcium hydroxylapatite (CaHA) in a gel bearer (Coaptite, ethylene vinyl alcohol copolymer inserts (e.g., Tegress, in the past Uryx), and polydimethylsiloxane (silicone, macroplastique).

injectable bulking agents market

Regional Outlook

On the basis of regional presence, the global injectable bulking agents market is segmented into six key regions viz. North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan, and Middle East & Africa. North America will continue to dominate the global market due to the availability of advanced technologies and more number of laboratory developed tests. Europe is expected to hold second large market share in the global injectable bulking agents market due to growing prevalence of urinary conditions and fecal incontinence. Many non-FDA-approved injectable bulking agents are also in use in many developed and developing economies, e.g., dextranomer/hyaluronic acid with injection system is used to deliver the bulking agent in the outpatient clinic setting without need for endoscopy.

Key Market Vendors

Medium- and Large-Scale Manufacturers/Providers

  • Allergan Plc.

  • Advanced UroScience

  • CR Bard

  • Merz Aesthetics

  • Cogentix Medical

  • Q-Med


  • Coloplast Corp

  • Boston Scientific Corporation

  • AstraZeneca

  • Others

Research Methodology

The market sizing of injectable bulking agents will be done by the adoption data triangulation approach. Demand-side approach will be followed to assess the actual market size of injectable bulking agents. Secondary research will be done at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analyzed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and drug manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing. 

Key Data Points Covered in Report

  • The report covers exhaustive analysis on:
  • Injectable Bulking Agents Market by route of administration, end user and region
  • Regional level market analysis of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Middle East & Africa by route of administration, end use segments and country
  • Injectable Bulking Agents Market Dynamics & Opportunity Assessment
  • Historical Actual Market Size, 2013 - 2017
  • Injectable Bulking Agents Market Size & Forecast 2018-2028
  • Injectable Bulking Agents Current Trends/Issues/Challenges
  • Competition & Companies involved

Report Highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size, recent industry trends
  • Key competition landscape, market structure, regulatory scenario
  • Epidemiology outlook for diseases
  • Economical spending, regional healthcare outlook, consumer healthcare expenditure
  • Strategies for key players and product offerings, channel strategies, regional foot print, channel footprint
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance in terms of value and volume

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Injectable Bulking Agents Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

The global market for Injectable bulking agents market is segmented on the basis of disease indication, end user and geography.

By Disease Indication:

  • Stress Urinary Incontinence
  • Fecal Incontinence
  • Other Female Urinary Deficiency Disorders

By End Users:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Others

Report Highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size, recent industry trends
  • Key competition landscape, market structure, regulatory scenario
  • Epidemiology outlook for diseases
  • Economical spending, regional healthcare outlook, consumer healthcare expenditure
  • Strategies for key players and product offerings, channel strategies, regional foot print, channel footprint
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance in terms of value and volume
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Injectable Bulking Agents Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Injectable Bulking Agents Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Akshay Godge

Akshay Godge

Client Partner - Global Business Development

Our Clients

Request Sample Request customization Request Methodology